Hospital-acquired pneumonia is associated with high rates of morbidity and mortality, and dissemination to the bloodstream is a recognized risk factor for particularly poor outcomes. Yet the mechanism by which bacteria in the lungs gain access to the bloodstream remains poorly understood. In this study, we used a mouse model of Pseudomonas aeruginosa pneumonia to examine this mechanism. P. aeruginosa uses a type III secretion system to deliver effector proteins such as ExoS directly into the cytosol of eukaryotic cells. ExoS, a bi-functional GTPase activating protein (GAP) and ADP-ribosyltransferase (ADPRT), inhibits phagocytosis during pneumonia but has also been linked to a higher incidence of dissemination to the bloodstream. We used a novel imaging methodology to identify ExoS intoxicated cells during pneumonia and found that ExoS is injected into not only leukocytes but also epithelial cells. Phagocytic cells, primarily neutrophils, were targeted for injection with ExoS early during infection, but type I pneumocytes became increasingly injected at later time points. Interestingly, injection of these pneumocytes did not occur randomly but rather in discrete regions, which we designate ““fields of cell injection” (FOCI). These FOCI increased in size as the infection progressed and contained dead type I pneumocytes. Both of these phenotypes were attenuated in infections caused by bacteria secreting ADPRT-deficient ExoS, indicating that FOCI growth and type I pneumocyte death were dependent on the ADPRT activity of ExoS. During the course of infection, increased FOCI size was associated with enhanced disruption of the pulmonary-vascular barrier and increased bacterial dissemination into the blood, both of which were also dependent on the ADPRT activity of ExoS. We conclude that the ADPRT activity of ExoS acts upon type I pneumocytes to disrupt the pulmonary-vascular barrier during P. aeruginosa pneumonia, leading to bacterial dissemination.
References
[1]
Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C (1999) The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 159: 1249–1256. pmid:10194173 doi: 10.1164/ajrccm.159.4.9807050
[2]
Magret M, Lisboa T, Martin-Loeches I, Manez R, Nauwynck M, et al. (2011) Bacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study. Crit Care 15: R62. doi: 10.1186/cc10036. pmid:21324159
[3]
Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, et al. (1989) Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Am Rev Respir Dis 139: 877–884. pmid:2930067 doi: 10.1164/ajrccm/139.4.877
[4]
George DL, Galk PS, Wunderink RG, Leeper KVJ, Meduri GU, et al. (1998) Epidemiology of ventilator-acquired pneumonia based on protected bronchoscopic sampling. Am J Respir Crit Care Med 158: 1839–1847. pmid:9847276 doi: 10.1164/ajrccm.158.6.9610069
[5]
Rello J, Gallego M, Mariscal D, Sonora R, Valles J (1997) The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 156: 196–200. pmid:9230747 doi: 10.1164/ajrccm.156.1.9607030
Planquette B, Timsit JF, Misset BY, Schwebel C, Azoulay E, et al. (2013) Pseudomonas aeruginosa ventilator-associated pneumonia. predictive factors of treatment failure. Am J Respir Crit Care Med 188: 69–76. doi: 10.1164/rccm.201210-1897OC. pmid:23641973
[8]
Hauser AR (2009) The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol 7: 654–665. doi: 10.1038/nrmicro2199. pmid:19680249
[9]
Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, et al. (2001) Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 183: 1767–1774. pmid:11372029 doi: 10.1086/320737
[10]
Hauser AR, Cobb E, Bodí M, Mariscal D, Vallés J, et al. (2002) Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 30: 521–528. pmid:11990909 doi: 10.1097/00003246-200203000-00005
[11]
Feltman H, Schulert G, Khan S, Jain M, Peterson L, et al. (2001) Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 147: 2659–2669. pmid:11577145
[12]
Frithz-Lindsten E, Du Y, Rosqvist R, Forsberg A (1997) Intracellular targeting of exoenzyme S of Pseudomonas aeruginosa via type III-dependent translocation induces phagocytosis resistance, cytotoxicity and disruption of actin microfilaments. Mol Microbiol 25: 1125–1139. pmid:9350868 doi: 10.1046/j.1365-2958.1997.5411905.x
[13]
Fleiszig SM, Wiener-Kronish JP, Miyazaki H, Vallas V, Mostov KE, et al. (1997) Pseudomonas aeruginosa-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S. Infect Immun 65: 579–586. pmid:9009316
[14]
Jia J, Wang Y, Zhou L, Jin S (2006) Expression of Pseudomonas aeruginosa toxin ExoS effectively induces apoptosis in host cells. Infect Immun 74: 6557–6570. pmid:16966406 doi: 10.1128/iai.00591-06
[15]
Kaufman MR, Jia J, Zeng L, Ha U, Chow M, et al. (2000) Pseudomonas aeruginosa mediated apoptosis requires the ADP-ribosylating activity of ExoS. Microbiology 146: 2531–2541. pmid:11021928
[16]
Angus AA, Lee AA, Augustin DK, Lee EJ, Evans DJ, et al. (2008) Pseudomonas aeruginosa induces membrane blebs in epithelial cells, which are utilized as a niche for intracellular replication and motility. Infect Immun 76: 1992–2001. doi: 10.1128/IAI.01221-07. pmid:18316391
[17]
Kudoh I, Wiener-Kronish JP, Hashimoto S, Pittet J-F, Frank D (1994) Exoproduct secretions of P. aeruginosa strains influence severity of alveolar epithelial injury. Am J Physiol 267(5 Pt 1): L551–L556. pmid:7977765
[18]
Shaver CM, Hauser AR (2004) Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect Immun 72: 6969–6977. pmid:15557619 doi: 10.1128/iai.72.12.6969-6977.2004
[19]
Nicas TI, Bradley J, Lochner JE, Iglewski BH (1985) The role of exoenzyme S in infections with Pseudomonas aeruginosa. J Infect Dis 152: 716–721. pmid:2995500 doi: 10.1093/infdis/152.4.716
[20]
Beasley MB, Travis W.D., Rubin E. (2008) The Respiratory System. In: Rubin R. Strayer DS, editor. Rubin's Pathology: Clinicopathologic. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins.
[21]
McCormack FX, Whitsett JA (2002) The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J Clin Invest 109: 707–712. pmid:11901176 doi: 10.1172/jci0215293
[22]
Rangel SM, Logan LK, Hauser AR (2014) The ADP-ribosyltransferase domain of the effector protein ExoS inhibits phagocytosis of Pseudomonas aeruginosa during pneumonia. MBio 5: e01080–01014. doi: 10.1128/mBio.01080-14. pmid:24917597
[23]
Zlokarnik G, Negulescu PA, Knapp TE, Mere L, Burres N, et al. (1998) Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. Science 279: 84–88. pmid:9417030 doi: 10.1126/science.279.5347.84
[24]
Verove J, Bernarde C, Bohn YS, Boulay F, Rabiet MJ, et al. (2012) Injection of Pseudomonas aeruginosa Exo toxins into host cells can be modulated by host factors at the level of translocon assembly and/or activity. PLoS One 7: e30488. doi: 10.1371/journal.pone.0030488. pmid:22299042
[25]
Charpentier X, Oswald E (2004) Identification of the secretion and translocation domain of the enteropathogenic and enterohemorrhagic Escherichia coli effector Cif, using TEM-1 beta-lactamase as a new fluorescence-based reporter. J Bacteriol 186: 5486–5495. pmid:15292151 doi: 10.1128/jb.186.16.5486-5495.2004
[26]
Marketon MM, DePaolo RW, DeBord KL, Jabri B, Schneewind O (2005) Plague bacteria target immune cells during infection. Science 309: 1739–1741. pmid:16051750 doi: 10.1126/science.1114580
[27]
Goehring U-M, Schmidt G, Pederson KJ, Aktories K, Barbieri JT (1999) The N-terminal domain of Pseudomonas aeruginosa exoenzyme S is a GTPase-activating protein for Rho GTPases. J Biol Chem 274: 36369–36372. pmid:10593930 doi: 10.1074/jbc.274.51.36369
[28]
Radke J, Pederson KJ, Barbieri JT (1999) Pseudomonas aeruginosa exoenzyme S is a biglutamic acid ADP-ribosyltransferase. Infect Immun 67: 1508–1510. pmid:10024602
[29]
Yahr TL, Barbieri JT, Frank DW (1996) Genetic relationship between the 53- and 49-kilodalton forms of exoenzyme S from Pseudomonas aeruginosa. J Bacteriol 178: 1412–1419. pmid:8631719
[30]
Sun J, Barbieri JT (2003) Pseudomonas aeruginosa ExoT ADP-ribosylates CT10 regulator of kinase (Crk) proteins. J Biol Chem 278: 32794–32800. pmid:12807879 doi: 10.1074/jbc.m304290200
[31]
Shaver CM, Hauser AR (2006) Interactions between effector proteins of the Pseudomonas aeruginosa type III secretion system do not significantly affect several measures of disease severity in mammals. Microbiology 152: 143–152. pmid:16385124 doi: 10.1099/mic.0.28368-0
[32]
Bruno TF, Woods DE, Mody CH (2000) Exoenzyme S from Pseudomonas aeruginosa induces apoptosis in T lymphocytes. J Leukoc Biol 67: 808–816. pmid:10857853
[33]
Vance RE, Rietsch A, Mekalanos JJ (2005) Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo. Infect Immun 73: 1706–1713. pmid:15731071 doi: 10.1128/iai.73.3.1706-1713.2005
[34]
Diaz MH, Shaver CM, King JD, Musunuri S, Kazzaz JA, et al. (2008) Pseudomonas aeruginosa induces localized immunosuppression during pneumonia in mammals. Infect Immun 76: 4414–4421. doi: 10.1128/IAI.00012-08. pmid:18663007
[35]
Tran CS, Rangel SM, Almblad H, Kierbel A, Givskov M, et al. (2014) The Pseudomonas aeruginosa type III translocon is required for biofilm formation at the epithelial barrier. PLoS Pathog 10: e1004479. doi: 10.1371/journal.ppat.1004479. pmid:25375398
[36]
Heiniger RW, Winther-Larsen HC, Pickles RJ, Koomey M, Wolfgang MC (2010) Infection of human mucosal tissue by Pseudomonas aeruginosa requires sequential and mutually dependent virulence factors and a novel pilus-associated adhesin. Cell Microbiol 12: 1158–1173. doi: 10.1111/j.1462-5822.2010.01461.x. pmid:20331639
[37]
Apodaca G, Bomsel M, Lindstedt R, Engel J, Frank D, et al. (1995) Characterization of Pseudomonas aeruginosa-induced MDCK cell injury: glycosylation defective host cells are resistant to bacterial killing. Infect Immun 63: 1541–1551. pmid:7890421
[38]
Woodworth BA, Tamashiro E, Bhargave G, Cohen NA, Palmer JN (2008) An in vitro model of Pseudomonas aeruginosa biofilms on viable airway epithelial cell monolayers. Am J Rhinol 22: 235–238. doi: 10.2500/ajr.2008.22.3178. pmid:18588754
[39]
Soong G, Parker D, Magargee M, Prince AS (2008) The type III toxins of Pseudomonas aeruginosa disrupt epithelial barrier function. J Bacteriol 190: 2814–2821. doi: 10.1128/JB.01567-07. pmid:18165298
[40]
Huber P, Bouillot S, Elsen S, Attree I (2014) Sequential inactivation of Rho GTPases and Lim kinase by Pseudomonas aeruginosa toxins ExoS and ExoT leads to endothelial monolayer breakdown. Cell Mol Life Sci 71: 1927–1941. doi: 10.1007/s00018-013-1451-9. pmid:23974244
[41]
Angus AA, Evans DJ, Barbieri JT, Fleiszig SM (2010) The ADP-ribosylation domain of Pseudomonas aeruginosa ExoS is required for membrane bleb niche formation and bacterial survival within epithelial cells. Infect Immun 78: 4500–4510. doi: 10.1128/IAI.00417-10. pmid:20732998
[42]
Maldonado-Arocho FJ, Green C, Fisher ML, Paczosa MK, Mecsas J (2013) Adhesins and host serum factors drive Yop translocation by yersinia into professional phagocytes during animal infection. PLoS Pathog 9: e1003415. doi: 10.1371/journal.ppat.1003415. pmid:23818844
[43]
Durand EA, Maldonado-Arocho FJ, Castillo C, Walsh RL, Mecsas J (2010) The presence of professional phagocytes dictates the number of host cells targeted for Yop translocation during infection. Cell Microbiol 12: 1064–1082. doi: 10.1111/j.1462-5822.2010.01451.x. pmid:20148898
[44]
Kuang Z, Hao Y, Walling BE, Jeffries JL, Ohman DE, et al. (2011) Pseudomonas aeruginosa elastase provides an escape from phagocytosis by degrading the pulmonary surfactant protein-A. PLoS One 6: e27091. doi: 10.1371/journal.pone.0027091. pmid:22069491
[45]
Rubio F, Cooley J, Accurso FJ, Remold-O'Donnell E (2004) Linkage of neutrophil serine proteases and decreased surfactant protein-A (SP-A) levels in inflammatory lung disease. Thorax 59: 318–323. pmid:15047952 doi: 10.1136/thx.2003.014902
[46]
Fleiszig SM, Evans DJ, Do N, Vallas V, Shin S, et al. (1997) Epithelial cell polarity affects susceptibility to P. aeruginosa invasion and cytotoxicity. Infect Immun 65: 2861–2867. pmid:9199460
[47]
Lee A, Chow D, Haus B, Tseng W, Evans D, et al. (1999) Airway epithelial tight junctions and binding and cytotoxicity of Pseudomonas aeruginosa. Am J Physiol 277: L204–217. pmid:10409249
[48]
Ganter MT, Roux J, Su G, Lynch SV, Deutschman CS, et al. (2008) Role of small GPTases and {alpha}v{beta}5 integrin in P. aeruginosa-induced increase in lung permeability. Am J Respir Cell Mol Biol. doi: 10.1165/rcmb.2007-0454oc
[49]
Matthay MA, Wiener-Kronish JP (1990) Intact epithelial barrier function is critical for the resolution of alveolar edema in humans. Am Rev Respir Dis 142: 1250–1257. pmid:2252240 doi: 10.1164/ajrccm/142.6_pt_1.1250
[50]
Akca O, Koltka K, Uzel S, Cakar N, Pembeci K, et al. (2000) Risk factors for early-onset, ventilator-associated pneumonia in critical care patients: selected multiresistant versus nonresistant bacteria. Anesthesiology 93: 638–645. pmid:10969295 doi: 10.1097/00000542-200009000-00011
[51]
Lange M, Hamahata A, Enkhbaatar P, Esechie A, Connelly R, et al. (2008) Assessment of vascular permeability in an ovine model of acute lung injury and pneumonia-induced Pseudomonas aeruginosa sepsis. Crit Care Med 36: 1284–1289. doi: 10.1097/CCM.0b013e318169ef74. pmid:18379256
[52]
Ware LB, Matthay MA (2001) Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 163: 1376–1383. pmid:11371404 doi: 10.1164/ajrccm.163.6.2004035
[53]
Ozer EA, Allen JP, Hauser AR (2014) Characterization of the core and accessory genomes of Pseudomonas aeruginosa using bioinformatic tools Spine and AGEnt. BMC Genomics 15: 737. doi: 10.1186/1471-2164-15-737. pmid:25168460
[54]
Diaz MH, Hauser AR (2010) Pseudomonas aeruginosa cytotoxin ExoU is injected into phagocytic cells during acute pneumonia. Infect Immun 78: 1447–1456. doi: 10.1128/IAI.01134-09. pmid:20100855
[55]
Yasmin L, Jansson AL, Panahandeh T, Palmer RH, Francis MS, et al. (2006) Delineation of exoenzyme S residues that mediate the interaction with 14-3-3 and its biological activity. FEBS J 273: 638–646. pmid:16420486 doi: 10.1111/j.1742-4658.2005.05100.x
[56]
Howell HA, Logan LK, Hauser AR (2013) Type III secretion of ExoU is critical during early Pseudomonas aeruginosa pneumonia. MBio 4: e00032–00013. doi: 10.1128/mBio.00032-13. pmid:23481600
[57]
Lee VT, Smith RS, Tummler B, Lory S (2005) Activities of Pseudomonas aeruginosa effectors secreted by the type III secretion system in vitro and during infection. Infect Immun 73: 1695–1705. pmid:15731070 doi: 10.1128/iai.73.3.1695-1705.2005
[58]
Vogel HJ, Bonner DM (1956) Acetylornithinase of Escherichia coli partial purification and some properties. J Biol Chem 218: 97–106. pmid:13278318
[59]
Nicas TI, Iglewski BH (1984) Isolation and characterization of transposon-induced mutants of Pseudomonas aeruginosa deficient in production of exoenzyme S. Infect Immun 45: 470–474. pmid:6086529
[60]
Hoang TT, Kutchma AJ, Becher A, Schweizer HP (2000) Integration-proficient plasmids for Pseudomonas aeruginosa: site- specific integration and use for engineering of reporter and expression strains. Plasmid 43: 59–72. pmid:10610820 doi: 10.1006/plas.1999.1441
[61]
Comolli JC, Hauser AR, Waite L, Whitchurch CB, Mattick JS, et al. (1999) Pseudomonas aeruginosa gene products PilT and PilU are required for cytotoxicity in vitro and virulence in a mouse model of acute pneumonia. Infect Immun 67: 3625–3630. pmid:10377148
[62]
Ecker RC, Rogojanu R, Streit M, Oesterreicher K, Steiner GE (2006) An improved method for discrimination of cell populations in tissue sections using microscopy-based multicolor tissue cytometry. Cytometry A 69: 119–123. pmid:16479616 doi: 10.1002/cyto.a.20219
[63]
Ecker RC, Steiner GE (2004) Microscopy-based multicolor tissue cytometry at the single-cell level. Cytometry A 59: 182–190. pmid:15170597 doi: 10.1002/cyto.a.20052
